NCT04442945View on ClinicalTrials.gov

Phase 1 Study of ANAVEX3-71

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 3, 2020

Primary Completion Date

September 30, 2021

Study Completion Date

October 30, 2021

Conditions
Healthy
Interventions
DRUG

ANAVEX3-71

Active oral dose of ANAVEX3-71

DRUG

Placebo

Oral placebo

Trial Locations (1)

5000

CMAX Clinical Research Pty Ltd, Adelaide

Sponsors
All Listed Sponsors
collaborator

Anavex Australia Pty Ltd.

INDUSTRY

lead

Anavex Life Sciences Corp.

INDUSTRY

NCT04442945 - Phase 1 Study of ANAVEX3-71 | Biotech Hunter | Biotech Hunter